- Home
- GNTA vs LTRN Comparison
GNTA vs LTRN Comparison
Compare GNTA & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | LTRN |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | Italy | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 22.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNTA | LTRN |
|---|---|---|
| Price | $1.60 | $3.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 330.0K |
| Earning Date | 03-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $1.11 |
| 52 Week High | $10.00 | $5.74 |
Technical Indicators
Market Signals| Indicator | GNTA | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 63.50 | 64.45 |
| Support Level | $1.30 | $3.25 |
| Resistance Level | $1.70 | $3.79 |
| Average True Range (ATR) | 0.35 | 0.43 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 54.68 | 63.84 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.